利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1469 条记录 (耗时 0.035 秒)

    Composite probiotics and use thereof
    92.
    发明授权
    Composite probiotics and use thereof 有权

    公开(公告)号：US11446342B2

    公开(公告)日：2022-09-20

    申请号：US16520366

    申请日：2019-07-24

    申请人： INFINITUS (CHINA) COMPANY LTD.

    发明人： Fangli Ma ,  Wei Chen ,  Gang Wang ,  Xiaofeng Zhu ,  Yuanyuan Wang ,  Junyong Xiao ,  Hao Zhang ,  Jianxin Zhao

    IPC分类号： A61K9/19 ,  A61K35/747 ,  A61K35/745

    摘要： The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-γ, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.

    COMPOSITION
    95.
    发明申请
    COMPOSITION 有权

    公开(公告)号：US20220241354A1

    公开(公告)日：2022-08-04

    申请号：US17611312

    申请日：2020-06-05

    申请人： MORINAGA MILK INDUSTRY CO., LTD.

    发明人： Shutaro Kubo ,  Mai Murata ,  Hirotsugu Oda

    IPC分类号： A61K35/745 ,  A61K9/00 ,  A61K38/40 ,  A61K35/20 ,  A61K31/702 ,  A23L33/00 ,  A23L33/19

    摘要： An object of the present invention is to provide a technique for further promoting growth of bacteria belonging to the genus Bifidobacterium. By combining lactoferrin and/or lactoferrin hydrolyzate, and human milk oligosaccharides, a synergistic growth promoting effect of the bacteria belonging to the genus Bifidobacterium is achieved. Preferably, the human milk oligosaccharides include one or more selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, and lactodifucotetraose. In addition, preferably, the bacteria belonging to the genus Bifidobacterium include one or more selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum.

    USES OF PANTOTHENIC ACID IN PREPARATION OF A COMPOSITION FOR TREATING AND/OR PREVENTING TUMORS
    100.
    发明申请
    USES OF PANTOTHENIC ACID IN PREPARATION OF A COMPOSITION FOR TREATING AND/OR PREVENTING TUMORS 有权

    公开(公告)号：US20220202754A1

    公开(公告)日：2022-06-30

    申请号：US17606177

    申请日：2019-05-05

    申请人： REVAISSANT (SHENZHEN) BIOSCIENCES CO., LTD.

    发明人： Qingqing CAI

    IPC分类号： A61K31/197 ,  A61K35/741 ,  A61K35/745 ,  A61K35/742 ,  A61P35/00

    摘要： Provided is a use of pantothenic acid in preparation of a composition for treating and/or preventing tumors. The present disclosure also discloses a use of metabolites of intestinal bacteria comprising pantothenic acid in preparation of a composition for treating and/or preventing tumors. Also provided is a use of intestinal bacteria capable of secreting metabolites comprising pantothenic acid in preparation of a composition for treating and/or preventing tumors. Pantothenic acid and metabolites of intestinal bacteria comprising pantothenic acid can significantly promote the accumulation of CD8+ cytotoxic T lymphocytes in tumor microenvironment, and significantly inhibit tumor growth, thereby achieving the effect of preventing and/or treating tumors.